Literature DB >> 10787114

Quality of life in patients with axonal polyneuropathy.

L L Teunissen1, M Eurelings, N C Notermans, J W Hop, J van Gijn.   

Abstract

"Quality of life" (QOL) measurement reflects the impact of a disease on the daily life of a patient, and this can be used as an outcome measure in clinical trials. QOL measurements are rarely used in patients with neuromuscular disease. The aim of this study was to determine whether QOL is reduced in chronic polyneuropathy, whether there is a relationship between QOL and objective measures of disease severity, and whether measuring QOL is a useful addition to the assessment of severity of polyneuropathy. We measured QOL in 90 patients with chronic axonal polyneuropathy (33 with hereditary motor and sensory neuropathy type II and 57 with chronic idiopathic axonal polyneuropathy) using the RAND 36-item Health Survey questionnaire (RAND-36). We compared the results with the QOL of a reference population, with summed motor and sensory scores, and with the Rankin scale for handicap. Patients had worse scores than the reference population on seven of eight areas of the RAND-36. Patients with both low motor and low sensory scores rated lower in physical and emotional areas than less impaired patients. A low Rankin score was related only to physical domains. We conclude that in patients with chronic axonal polyneuropathy the severity of disease can be assessed with a general QOL instrument, and that this provides additional information, particularly on areas related to emotional and social functioning.

Entities:  

Mesh:

Year:  2000        PMID: 10787114     DOI: 10.1007/s004150050562

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  9 in total

Review 1.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

Review 2.  Chronic idiopathic axonal polyneuropathy: a systematic review.

Authors:  Panagiotis Zis; Ptolemaios Georgios Sarrigiannis; Dasappaiah Ganesh Rao; Channa Hewamadduma; Marios Hadjivassiliou
Journal:  J Neurol       Date:  2016-03-09       Impact factor: 4.849

3.  Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I.

Authors:  J S Kalkman; M L Schillings; S P van der Werf; G W Padberg; M J Zwarts; B G M van Engelen; G Bleijenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

4.  Quality of Life in Patients with Gluten Neuropathy: A Case-Controlled Study.

Authors:  Panagiotis Zis; Ptolemaios Georgios Sarrigiannis; Dasappaiah Ganesh Rao; Marios Hadjivassiliou
Journal:  Nutrients       Date:  2018-05-23       Impact factor: 5.717

5.  Chronic idiopathic axonal polyneuropathy: Prevalence of pain and impact on quality of life.

Authors:  Panagiotis Zis; Ptolemaios G Sarrigiannis; Dasappaiah G Rao; Channa Hewamadduma; Marios Hadjivassiliou
Journal:  Brain Behav       Date:  2018-11-25       Impact factor: 2.708

6.  Clinical characteristics of patients with diabetic polyneuropathy: the role of clinical and electromyographic evaluation and the effect of the various types on the quality of life.

Authors:  N Ovayolu; E Akarsu; E Madenci; S Torun; O Ucan; M Yilmaz
Journal:  Int J Clin Pract       Date:  2008-04-10       Impact factor: 2.503

Review 7.  The epidemiology and risk factors of chronic polyneuropathy.

Authors:  Rens Hanewinckel; Marieke van Oijen; M Arfan Ikram; Pieter A van Doorn
Journal:  Eur J Epidemiol       Date:  2015-12-23       Impact factor: 8.082

Review 8.  Microangiopathy-A Potential Contributing Factor to Idiopathic Polyneuropathy: A Mini Review.

Authors:  Kristin Samuelsson; Rayomand Press
Journal:  Front Neurol       Date:  2018-02-12       Impact factor: 4.003

9.  Correlates of diabetic polyneuropathy of the elderly in Sub-Saharan Africa.

Authors:  Nadine Simo; Callixte Kuate-Tegueu; Steve Ngankou-Tchankeu; Jacques Doumbe; Youssoufa Maiga; Matteo Cesari; Jean-François Dartigues; Andre-Pascal Kengne; Maturin Tabue-Teguo
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.